Kurma Partners

Kurma Partners is a Paris-based venture capital firm focused on European life sciences, with an investment program spanning biotech, medical devices and medtech, and diagnostics across pre-seed, seed, and Series A stages. The firm has built its reputation as one of the more active early-stage life-sciences investors in continental Europe, with particular depth in the French biotech ecosystem and meaningful presence across the broader European market. Check sizes between five and twenty-five million dollars combined with an early-stage focus signal a fund willing to lead first institutional rounds in capital-intensive life-sciences companies, which is a relatively rare combination given the typical risk profile of early therapeutic and diagnostic investing.

The investment thesis concentrates on rigorous life-sciences innovation rather than on digital health or AI-enabled software. Kurma is explicit about its focus on biotech, medical devices, and diagnostics, and the firm’s diligence typically engages deeply with scientific founders, with academic advisors, and with regulatory pathway considerations. The fund is not AI-focused in the way that recent digital health funds position themselves, and founders building computational biology or AI-only platforms without a therapeutic, device, or diagnostic component should evaluate fit carefully. What Kurma offers that pure digital health funds cannot is genuine sector depth in regulated European life sciences, including the operating knowledge required to navigate European Medicines Agency pathways, CE marking for medical devices, and the European reimbursement landscape that shapes commercial outcomes for diagnostics companies. For founders coming out of European academic medical centers and research universities with discovery-stage assets, Kurma represents one of the more active early checks in the European life-sciences ecosystem.

This profile does not include a specific list of portfolio companies. Founders should consult Kurma Partners’ portfolio page and pay attention to which biotech and medical device investments have progressed from preclinical or early clinical stages through to later milestones inside the portfolio. The progression pattern reveals which scientific subsectors the partnership has built conviction in, and which early bets have been backed with follow-on capital. Founders should also identify which portfolio companies have attracted follow-on investment from larger European life-sciences specialists or from US healthcare crossover funds, since those syndications often signal which Kurma-backed companies are positioned for transatlantic expansion.

The five to twenty-five million dollar check size range at pre-seed, seed, and Series A places Kurma in the rare position of being able to lead first institutional rounds with substantial capital. For early-stage life-sciences companies, this matters because therapeutic and device development often requires meaningful first checks to fund preclinical and early clinical work, and many early-stage funds simply cannot write checks at the size required. Kurma’s flexibility across the early-stage continuum allows founders to assemble a smaller, higher-conviction syndicate at the first institutional round rather than piecing together capital from many smaller checks. The fund syndicates frequently with other European life-sciences specialists, with French strategic corporate venture arms, and with regional life-sciences investors across continental Europe. At Series A and later, Kurma’s reserves support pro-rata participation, though founders should plan for larger institutional leads to anchor subsequent rounds.

Team member names are not enumerated in the source data for this profile. Founders should consult Kurma Partners’ website to identify the current investing team and pay particular attention to which partners have prior pharmaceutical operating experience, prior medical device commercialization roles, or academic clinical research backgrounds. The firm has historically built a partnership weighted toward technical and scientific depth in life sciences, and decision-making is partnership-driven with formal investment committee approval. Founders should expect deep diligence on scientific mechanism, on preclinical and early clinical strategy, and on regulatory pathway considerations.

The most reliable path into Kurma Partners is a warm introduction from a portfolio founder, from an academic researcher with a prior relationship with the firm, or from a co-investor in European life sciences. The French and broader European life-sciences community is dense and partner-driven, and introductions through known channels carry significantly more weight than cold inbound. Founders coming out of European academic medical centers, research universities, and biotech accelerators often find that their academic supervisors or clinical advisors can provide direct introductions to Kurma’s investing partners. Communication should be science-first, with detailed mechanism-of-action and preclinical-data framing rather than commercial-narrative pitching.

Founders should approach Kurma Partners when they are building an early-stage biotech, medical device, or diagnostics company in Europe, when they have meaningful preclinical or technical validation, and when they are raising at pre-seed, seed, or Series A. The firm is not the right fit for digital health, AI-only platforms without a therapeutic or device component, or late-stage growth rounds. It is an excellent fit for European biotech founders with discovery-stage or preclinical therapeutic programs, for medical device companies with European regulatory pathways, and for diagnostics companies addressing meaningful clinical or commercial questions. The fund’s depth in European life sciences and its willingness to lead first institutional rounds at meaningful check sizes are genuine differentiators in a continental market where early-stage life-sciences capital is often fragmented.